ThermiVa is an in office, nonsurgical, pain-free procedure for vaginal laxity, decreased sexual sensation and labia majora rejuvenation. ThermiVa treatments use radiofrequency energy to gently heat the internal (vaginal) and external (vulvar) tissue to restore, revive and rejuvenate feminine wellness. Three 30-minute in-office treatment sessions will help to restore vaginal / vulvar tone and function enhancing friction and sensation during intercourse. Peri / Post-menopausal women may also have improved vaginal lubrication and increased clitoral sensitivity following treatment.
ThermiVa is very similar to other non-surgical vaginal rejuvenation treatment options such as the Mona-Lisa Touch, or the FemiLift, however Dr. Miklos and Moore feel ThermiVa is the safest and gives the best non-surgical results compared to other non-surgical treatment options. Please click to the right to see Drs Miklos & Moore TV interview on ThermiVa.
ThermiVa has been found to be effective in reducing vaginal dryness, urinary leakage and improving orgasms. Content represents the views of the author. Not all claims have been cleared by the FDA.

Individual results may vary.

Our nurse practitioner will complete a thorough history and physical examination prior to treatment session and give recommendations on what they feel the most appropriate and best treatment option is for each individual patient. In more severe cases of prolapse (i.e. dropped bladder), urinary leakage, or severe laxity caused by vaginal childbirth or aging, surgical rejuvenation may be recommended as ThermiVa is not indicated for this type of more severe damage. ThermiVa is not FDA approved for laxity, incontinence, dryness or prolapse. The ThermiVa system and probes are FDA cleared (K130689) and indicated for use in dermatological and general surgical procedures for electrocoagulation and hemostasis; creation of lesions in nervous tissue. Click Here to read Thermi’s Response to FDA comments.

Dr. Marco Pelosi III Research on EBD

Editorial by reputable colleague Dr. Marco Pelosi III, who conducted some research on the most recent reports associated with the use of transvaginal energy-based devices (tv-EBD) for vaginal rejuvenation treatments. Dr. Pelosi completes a deep dive into the MAUDE database and provides specific insights regarding the adverse reports submitted to the FDA regarding the safe use of these devices.

Harvard Opinion on EBD

Editorial by Harvard Health Publishing on how the FDA warning on vaginal laser procedures should emphasize informed choices for vaginal rejuvenation treatments, instead of rising fear and confusion regarding this technology’s ability to successfully treat symptoms related to sexual function, vaginal laxity, and stress urinary incontinence.

APOPS Commentary on EBD

Editorial by the Association for Pelvic Organ Prolapse Support on how vaginal tissue rejuvenation non-surgical procedures to treat pelvic organ prolapse it’s in fact very effective in providing relief to women experiencing pelvic organ prolapse symptoms. The article provides feedback from patients and practitioners on the successful use of this technology.

Transcutaneous Temperature Controlled Radiofrequency for Orgasmic Dysfunction

Article by Dr. Red M. Alinsod that evaluates the safety, tolerability, and clinical efficacy of transcutaneous temperature-controlled radiofrequency (TTCRF) on vulvovaginal tissue for orgasmic dysfunction.

Review & Clinical Experience Exploring Evidence, Clinical Efficacy, & Safety Regarding Nonsurgical Treatment of Feminine Rejuvenation

Article published by the Journal of Cosmetic Dermatology reviews the use of energy-based devices for feminine genital rejuvenation of mild and moderate conditions as an effective and safe option for patients looking to improve function and esthetic vaginal health.

Transcutaneous Temperature Controlled Radiofrequency (TTCRF) for the Treatment of Menopausal Vaginal/Genitourinary Symptoms

Article published by Surgical Technology International evaluates the effects of non-ablative, monopolar transcutaneous temperature-controlled radiofrequency technology in the treatment of postmenopausal women suffering from genuine stress urinary incontinence related to menopause.

Histologic and Clinical Changes in Vulvovaginal Tissue After Treatment with a Transcutaneous Temperature-Controlled Radiofrequency Device

Article by the American Society of Dermatologic Surgery evaluates clinical and histological changes induced by vulvovaginal TTCRF and encounters significant improvements in atrophic vaginitis, vulvovaginal laxity, and sexual satisfaction with milder improvements in orgasmic dysfunction and stress urinary incontinence.